Q: What is Eli Lilly 2024/Q1 Earnings Preview?
TigerGPT Answer: 【Forecast Data】
Eli Lilly and Co (LLY) is forecasted to have an Earnings Per Share (EPS) of $2.46 for Q1 2024. The total revenue estimate is $8,922,458,560, and the EBIT estimate is $2,678,557,290 for the same quarter. Compared to Q1 2023, the EPS has increased by 51.85%, total revenue by 28.15%, and EBIT by 65.42%. These significant increases suggest a strong growth trajectory for the company, reflecting successful product launches, increased demand for its products, or improved operational efficiency.
【Quarterly Important News】
Key news over the past quarter includes:
1. German Chancellor Olaf Scholz's commitment to support the pharmaceutical industry, which could create a favorable environment for Eli Lilly's operations in Germany.
2. Eli Lilly's acquisition of a manufacturing facility from Nexus Pharmaceuticals, which is expected to enhance its production capabilities for injectable medicines.
These developments are likely to have a positive impact on Eli Lilly's operational efficiency and market reach, potentially contributing to the financial performance reflected in the current report and future growth.
【Forecast Viewpoints】
Analysts expect a rise in Eli Lilly's quarterly revenue and have revised the EPS estimate slightly higher over the last 30 days, indicating a positive outlook on the company's performance. The anticipated growth is driven by strong demand for new medicines like tirzepatide, Mounjaro, and Zepbound. Here are some viewpoints from relevant articles:
- Eli Lilly expected to post earnings of $2.46 a share - Earnings Preview: Earnings Preview
- Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics: Wall Street Estimates
- Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?: Portfolio Consideration
【Stock Trend Analysis】
Eli Lilly's stock price has seen a quarterly fluctuation of 33.46% from the end of the previous quarter to the end of March 2024. The latest stock price as of April 27, 2024, is $734.08, with a support level at $738.7 and a resistance level at $709.7. The stock has been performing well, with a positive trend, but it is currently trading near the support level, which could indicate a potential trend reversal if the support level is broken.
【Options Large Order Analysis】
The options large orders show a series of sell orders for call options at various strike prices. This could indicate that some traders are expecting the stock to not rise above these strike prices by the expiration dates, suggesting a bearish sentiment or a strategy to collect premium on the options sold.
【Analyst Ratings and Target Price Forecast】
With 8 recommendations to recommend, 13 to buy, and 7 to hold, analysts seem to have a generally positive view of Eli Lilly. The mean target price is $826.94, with a low estimate of $540 and a high estimate of $1000. This suggests that the company is currently trading below the mean target price, indicating potential undervaluation and room for growth if the financial report meets or exceeds expectations.
【Comprehensive Conclusion】
Eli Lilly is expected to report strong financial results for Q1 2024, with significant growth in EPS, revenue, and EBIT. The company's strategic investments and favorable industry support are likely to contribute positively to its performance. The stock has shown a strong upward trend, but recent options activity and proximity to the support level suggest caution. Analysts have a positive outlook, with the stock potentially undervalued based on target price estimates.
Disclaimer: The above content is generated by the AI robot TigerGPT and does not represent any personal views. The content is for reference only and does not constitute any investment advice.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
